Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon α combined with paclitaxel

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2413-2422

  Tedjarati, Sean ^a   Baker, Cheryl H ^a   Apte, Sachin ^a   Huang, Suyun ^a   Wolf, Judith K ^a   Killion, Jerald J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CYCLINE; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; INTERLEUKIN 8; LYMPHOKINE; MACROGOL DERIVATIVE; PACLITAXEL; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A; ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR;

ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG EFFECT; DRUG POTENTIATION; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; MOUSE; NICK END LABELING; NORTHERN BLOTTING; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOFLUORESCENCE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, NORTHERN; CELL DIVISION; DRUG SYNERGISM; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERLEUKIN-8; LYMPHOKINES; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; ANIMAL; GELATINASE B; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035992432     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Cancer statistics, 1999
2. Trends in United States ovarian cancer mortality, 1979-1995
3. Cancer of the ovary
4. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
5. Carboplatin and paclitaxel in ovarian carcinoma: A Phase I study of the Gynecologic Oncology Group
6. Virus interference. I. The interferon
7. The interferons: A biological system with therapeutic potential in viral infections
8. Role of interferons in the regulation of cell proliferation, differentiation, and development
9. Cytokine therapeutics: Lessons from interferon-α
10. Interferons in malignancy: Biological products or biological response modifiers?
11. Effects of interferons and other cytokines on tumors in animals: A review
12. Organ-site dependent expression of bFGF in human renal cell carcinoma cells
13. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells
14. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β
15. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon-α-2b
16. Down-regulation of interleukin-8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition of interferon
17. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells
18. Interaction of interferons with skin reactive cytokines: From interleukin-1 to interleukin-8
19. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice
20. Human recombinant interferons-β and-γ and decreased gelatinase production and invasion by human KG-2 renal carcinoma cells
21. Suppression of gelatinase production with decreased invasiveness of choriocarcinoma cells by human recombinant interferon-β
22. Interferon-β treatment of metastatic prostate cancer
23. Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma
24. Human lymphoblastic interferon in the treatment of advanced epithelial ovarian malignancies: A Gynecologic Oncology Group study
25. Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
26. Intraperitoneal human recombinant interferon-α-2b in minimal residual ovarian cancer
27. Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study
28. A Phase III trial of intraperitoneal cisplatin and α interferon in patients with persistent epithelial ovarian cancer
29. Intraperitoneal carboplatin with or without interferon-α in advanced ovarian cancer patients with minimal residual disease at second look: A prospective randomized trial of III patients
30. Intraperitoneal recombinant α-2-interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer: A Phase II study
31. Clinical pharmacokinetics of interferons
32. Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines
33. Interferons a and β downregulate the expression of basic fibroblast growth factor in human carcinomas
34. Interferon-α mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
35. Direct and indirect effects of human recombinant γ-interferon on tumor cells in a clonogenic assay
36. Intraperitoneal administration of the biologic agents tumor necrosis factor, γ-interferon, and interleukin-2
37. Identification of the major positional isomer of pegylated interferon α-2b
38. Rational design of a potent, long-lasting form of interferon: A 40-kDa branched polyethylene glycol-conjugated interferon α-2 for the treatment of hepatitis C
39. Structural and biological characterization of pegylated recombinant interferon-α-2b
40. A randomized, double blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C
41. Peginterferon-α-2a (40 kD): A review of its use in the management of chronic hepatitis C
42. Efficacy and safety of pegylated (40 kD) interferon-α-2a compared with interferon-α-2a in noncirrhotic patients with chronic hepatitis C
43. Phase I trial of 40-kD branched pegylated interferon α-2a for patients with advanced renal cell carcinoma
44. New human tumor cell lines
45. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
46. Amplification and rearrangement of the Kirsten ras oncogene in virus-transformed BALB/c 3T3 cells during malignant tumor progression
47. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigene family
48. Structure and function of a new STAT-induced STAT inhibitor
49. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
50. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
51. Reciprocal paracrine interactions between tumour cells and endothelial cells: The "angiogenesis progression" hypothesis
52. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
53. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
54. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice
55. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma
56. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
57. The SOCS proteins: A new family of negative regulators of signal transduction
58. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
59. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis
60. The implications of angiogenesis to the biology and therapy of cancer metastasis
61. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
62. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
63. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues
64. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling
65. Inhibition of Statl-mediated gene activation of PIAS1